Welcome to our dedicated page for Transmedics Group SEC filings (Ticker: TMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TransMedics Group, Inc. filings document a Nasdaq-listed medical technology company built around the Organ Care System, National OCS Program and related transplant logistics services for lung, heart and liver transplantation. Its 8-K reports furnish operating results, guidance, tax valuation allowance disclosures and business drivers such as OCS case utilization, logistics revenue and aircraft assets.
Other filings cover material agreements, including headquarters facilities and completed aircraft acquisitions, as well as executive transitions, compensatory arrangements, inducement awards and proxy-governance matters. The company's disclosures also describe its common stock listing, board and shareholder voting matters, executive compensation, clinical program updates and FDA-related device disclosures.
TransMedics Group, Inc. officer Nicholas Corcoran reported equity compensation awards. He received 11,727 restricted stock units (RSUs), each representing a contingent right to one share of common stock, bringing his direct common stock holdings to 41,558 shares.
He was also granted a stock option for 17,784 shares of common stock at an exercise price of $71.23 per share, expiring on July 10, 2036. The option vests at 2.0833% per month starting after April 10, 2026 and is scheduled to be fully vested by April 10, 2030, subject to continued service.
Hernandez Gerardo reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. Chief Financial Officer Gerardo Hernandez received equity awards on 2026-07-10 consisting of 17,246 RSUs, each representing one share of common stock, and stock options for 26,153 shares at $71.23 per share, vesting monthly from April 10, 2026 through April 10, 2030. Following these grants, he holds 31,935 common shares directly and 26,153 options expiring July 10, 2036.
Hassanein Waleed H reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group President & CEO Waleed H. Hassanein received equity awards on July 10, 2026, including 49,669 restricted stock units and stock options for 112,984 shares at $71.23 per share, vesting monthly from April 2026 to April 2030.
Following these awards, he holds 171,093 shares directly and options on 112,984 shares, plus indirect holdings of 150,000 shares through the Hassanein 2026 Qualified Annuity Trust and 345,009 shares through the Waleed H. Hassanein Revocable Trust; a 150,000‑share transfer between these trusts was a change in the form of beneficial ownership exempt under Rule 16a-13.
TransMedics Group director Thomas J. Gunderson exercised stock options and sold shares in a related move. He exercised options for 19,285 shares of common stock at an exercise price of $2.21 per share and sold 9,624 shares at $75.06 per share to cover the exercise price and tax withholding obligations. After these transactions, he directly held 26,266 shares of TransMedics common stock. The options exercised were granted on August 1, 2016 and are fully vested, and no related derivative position remains from this grant.
Lovell Stephanie reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director Stephanie Lovell received an equity award in the form of restricted stock units. On May 20, 2026, she was granted 2,922 shares of common stock at a price of $0.00 per share as a compensation-related award, not an open-market purchase. Each restricted stock unit represents a contingent right to receive one share of TransMedics common stock. Following this grant, Lovell directly holds 5,788 shares of the company’s common stock.
Weill David reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director David Weill reported an equity compensation grant of 2,922 shares of common stock in the form of restricted stock units. Each RSU represents a contingent right to receive one share of common stock, with no cash paid per share. Following this award, Weill directly holds 15,056 shares of TransMedics common stock, reflecting a routine compensation-related increase in his ownership rather than an open-market purchase.
RAINES MERILEE reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group director Merilee Raines received an equity grant of 2,922 restricted stock units (RSUs) on common stock. These RSUs are a form of stock-based compensation, with each unit representing the right to receive one TransMedics common share. Following this award, Raines directly holds 6,981 common shares.
Gunderson Thomas J. reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director Thomas J. Gunderson received an equity award of 2,922 restricted stock units. These RSUs were granted at no cash cost and each unit represents the right to receive one share of common stock. Following this grant, he directly holds 6,981 shares and RSUs in total, reflecting routine, compensation-related ownership rather than an open-market purchase or sale.
Basile Edward M reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director Edward M. Basile received a grant of 2,922 shares of common stock in the form of restricted stock units. The award was made at no cash cost per share and is a form of equity compensation. Following this grant, Basile directly holds 5,788 shares of the company’s common stock, showing his stake has increased through stock-based awards rather than open-market purchases or sales.